Pharmacotherapy of male hypogonadism

Rastrelli, Giulia; Vignozzi, Linda; Corona, Giovanni; Maggi, Mario

doi:10.1016/j.coph.2022.102323

Cited by 4 publications

(7 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, T preparations should not be used when fertility is desired, at least in secondary (central) hypogonadism. In that case, the use of Gn-releasing hormone (GnRH) or Gn themselves represents the treatment of choice [18,29]. However, GnRH does not offer any advantage despite a higher cost when compared to Gn [18].…”

Section: Challengesmentioning

confidence: 99%

“…In that case, the use of Gn-releasing hormone (GnRH) or Gn themselves represents the treatment of choice [18,29]. However, GnRH does not offer any advantage despite a higher cost when compared to Gn [18]. A previous use of TRT did not negatively affect responsiveness to subsequent Gn therapy, as derived from meta-analysis [18].…”

Section: Challengesmentioning

confidence: 99%

“…The former possibility is more obvious. In fact, several medical conditions characterized by an increased CV risk, such as diabetes mellitus (DM), metabolic syndrome (MetS), and obesity, show a 2-3 fold increased prevalence of LOH [17][18][19][20]. LOH in the latter conditions is now also called 'functional hypogonadism' because it is potentially reversible by treating the underlying metabolic derangements [18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

“…In fact, several medical conditions characterized by an increased CV risk, such as diabetes mellitus (DM), metabolic syndrome (MetS), and obesity, show a 2-3 fold increased prevalence of LOH [17][18][19][20]. LOH in the latter conditions is now also called 'functional hypogonadism' because it is potentially reversible by treating the underlying metabolic derangements [18][19][20][21]. On the other hand, it is less clear if pharmacological treatment of LOH with TRT is able to decrease the risk of CV events in otherwise hypogonadal subjects.…”

Section: Introductionmentioning

confidence: 99%

“…physical exercise), or even bariatric surgery, is efficient in restoring normal T levels [20,21,24,25] and is recommended as the first approach by some of the available guidelines [3,6]. Although the aforementioned lifestyle measures are indeed effective in increasing T levels [18,21], the long-term outcomes of dieting and physical exercise are frequently negative, and bariatric surgery is not cost-effective. On the other hand, the cost of TRT should also be considered and discussed with the patients.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Developments and challenges for new and emergent preparations for male hypogonadism treatment

Corona,

Sparano,

Rastrelli

et al. 2023

Expert Opinion on Investigational Drugs

Self Cite

View full text Add to dashboard Cite

Introduction:The specific role of testosterone (T) replacement therapy in patients with late onset hypogonadism is still conflicting. Several available preparations have been developed to restore either fertility and normal testosterone (T) levels (secondary hypogonadism) or just T levels (primary hypogonadism). Areas covered: Advantages and limitations related to available new treatments will be discussed in detail. In addition, possible news related to preparations in the pipeline will be discussed. Expert opinion:The selection of a specific T preparation should be adequately discussed with each subject. Transdermal T preparations are those that can preserve, after a unique morning administration, the circadian rhythmicity of T secretion. Conversely, short-acting preparations (such as oral or intranasal) need two-or threetimes daily administration, potentially reducing patient compliance. Long acting T preparations, such as injectable T undecanoate have the advantage of bimestrial or trimestral administration, reducing the required number of administrations. The use of non-steroidal selective androgen receptor modulators (SARM), a heterogeneous class of compounds selectively acting on androgen receptor targets, remains investigational due to the lack of the full spectrum of T's action and the possible risk of side effects, despite their potential use in the treatment of muscle wasting and osteoporosis.

show abstract

Section: Challengesmentioning

confidence: 99%